Fingolimod-d4

Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].

Product Specifications

CAS Number

[1346747-38-3]

Product Name Alternative

FTY720 free based-d4

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

LPL Receptor; PAK

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein

Field of Research

Cancer; Inflammation/Immunology

Purity

99.11

Solubility

10 mM in DMSO|DMF : ≥ 20mg/mL|DMSO : ≥ 10mg/mL|Ethanol : ≥ 5mg/mL

Smiles

OC([2H])([2H])C(CCC1=CC=C(CCCCCCCC)C=C1)(N)C([2H])([2H])O

Molecular Formula

C19H29D4NO2

Molecular Weight

311.50

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Rolin J, et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010, 59 (4), 575-586.|[3]Szepanowski F, et al. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. J Neuroinflammation. 2016 Jun 10;13 (1) :143.|[4]Airas L, et al. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. J Nucl Med. 2015 Feb;56 (2) :305-10.|[5]Shirakabe K, et al. Modification of lymphocyte migration to Peyer's patches by inhibition of sphingosine-1-phosphate lyase ameliorates murine colitis. J Gastroenterol Hepatol. 2018 Jan 15.